Synthesis and Biological Evaluation of Novel 4,5,6,7-Tetrahydrobenzo[D]-Thiazol-2- Yl Derivatives Derived from Dimedone with Anti-Tumor, C-Met, Tyrosine Kinase and Pim-1 Inhibitions

Author(s): Rafat M. Mohareb*, Amr S. Abouzied, Nermeen S. Abbas

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Volume 19 , Issue 12 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Dimedone and thiazole moieties are privileged scaffolds (acting as primary pharmacophores) in many compounds that are useful to treat several diseases, mainly tropical infectious diseases. Thiazole derivatives are a very important class of compounds due to their wide range of pharmaceutical and therapeutic activities. On the other hand, dimedone is used to synthesize many therapeutically active compounds. Therefore, the combination of both moieties through a single molecule to produce heterocyclic compounds will produce excellent anticancer agents.

Objective: The present work reports the synthesis of 47 new substances belonging to two classes of compounds: Dimedone and thiazoles, with the purpose of developing new drugs that present high specificity for tumor cells and low toxicity to the organism. To achieve this goal, our strategy was to synthesize a series of 4,5,6,7-tetrahydrobenzo[d]-thiazol-2-yl derivatives using the reaction of the 2-bromodimedone with cyanothioacetamide.

Methods: The reaction of 2-bromodimedone with cyanothioacetamide gave the 4,5,6,7-tetrahydrobenzo[d]- thiazol-2-yl derivative 4. The reactivity of compound 4 towards some chemical reagents was observed to produce different heterocyclic derivatives.

Results: A cytotoxic screening was performed to evaluate the performance of the new derivatives in six tumor cell lines. Thirteen compounds were shown to be promising toward the tumor cell lines which were further evaluated toward five tyrosine kinases.

Conclusion: The results of antitumor screening showed that many of the tested compounds were of high inhibition towards the tested cell lines. Compounds 6c, 8c, 11b, 11d, 13b, 14b, 15c, 15g, 21b, 21c, 20d and 21d were the most potent compounds toward c-Met kinase and PC-3 cell line. The most promising compounds 6c, 8c, 11b, 11d, 13b, 14b, 15c, 15g, 20c, 20d, 21b, 21c and 21d were further investigated against tyrosine kinase (c-Kit, Flt-3, VEGFR-2, EGFR, and PDGFR). Compounds 6c, 11b, 11d, 14b, 15c, and 20d were selected to examine their Pim-1 kinase inhibition activity the results revealed that compounds 11b, 11d and 15c had high activities.

Keywords: Dimedone, thiazole, thiophene multi-component, tyrosine kinase, cyanothioacetamide, tyrosine kinase.

[1]
Zhao, H.; Cui, G.; Jin, J.; Chen, X.; Xu, B. Synthesis and Pin1 inhibitory activity of thiazole derivatives. Bioorg.& Med. Chem., 2016, 24(22), 5911-5920.
[2]
Taha, M.; Ismail, N.H.; Imran, S.; Selvaraj, M.; Rahim, F. Synthesis of novel inhibitors of β-glucuronidase based on the benzothiazole skeleton and their molecular docking studies. RSC Advances, 2016, 6, 3003-3012.
[3]
Mouri, K.; Saito, S.; Yamaguchi, S. Highly flexible p-expanded cyclooctatetraenes: cyclic thiazole tetramers with head-to-tail connection. Angew. Chem. Int. Ed., 2012, 51, 5971-5975.
[4]
Shah, N.K.; Shah, N.M.; Patel, M.P.; Patel, R.G. Synthesis, characterization and antimicrobial activity of some new biquinoline derivatives containing a thiazole moiety. Chin. Chem. Lett., 2012, 23, 454-457.
[5]
Mukhopadhyay, C.; Ray, S. Rapid and straightforward one-pot expeditious synthesis of 2-amino-5-alkylidene-thiazol-4-ones at room temperature. Tetrahedron Lett., 2011, 52, 6431-6438.
[6]
Heravi, M.M.; Moghimi, S. An efficient synthesis of thiazol-2-imine derivatives via a one-pot, three-component reaction. Tetrahedron Lett., 2012, 53, 392-394.
[7]
Li, Z.; Yang, Q.; Qian, X. Novel heterocyclic family of phenyl naphthothiazole carboxamides derived from naphthalimides: Synthesis, antitumor evaluation, and DNA photocleavage. Bioorg. Med. Chem., 2005, 13, 3149-3155.
[8]
Li, Y.; Xu, Y.; Qianb, X.; Qu, B. Naphthalimide-thiazoles as novel photonucleases: molecular design, synthesis, and evaluation. Tetrahedron Lett., 2004, 45, 1247-1251.
[9]
De Souza, M.V.N. Synthesis and biological activity of natural thiazoles: An important class of heterocyclic compounds. J. Sulfur Chem., 2005, 26, 429-449.
[10]
Shi, Q.; Liu, S.; Wood, M.K.; Shao, H.; Shi, L. Long-term outcomes associated with triple-goal achievement in patients with type 2 diabetes mellitus (T2DM). Diabetes Res. Clin. Pract., 2018, 140, 45-54.
[11]
Qiu, X.L.; Li, G.; Wu, G.; Zhu, J.; Zhou, L.; Chen, P.L.; Chamberlin, A.R.; Lee, W.H. Synthesis and biological evaluation of a series of novel inhibitor of Nek2/Hec1 Analogues. J. Med. Chem., 2009, 52, 1757-1767.
[12]
Tsoua, H.; MacEwan, G.; Birnberg, G.; Grosu, G.; Bursavich, M.G.; Bard, J.; Brooijmansa, N.; Toral-Barzab, L.; Hollanderb, I.; Mansoura, T.S.; Ayral-Kaloustiana, K.; Yub, S. Discovery and optimization of 2-(4-substituted-pyrrolo[2,3-b]pyridin-3-yl)methylene-4-hydroxy-benzofuran-3(2H)-ones as potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR). Bioorg. Med. Chem. Lett., 2010, 20, 2321-2325.
[13]
Mohammed, H.B.; Hemant, K.S.; Garikapati, N.S. Analogue-based approaches in anti-cancer compound modelling: the relevance of QSAR models. Org. Med. Chem. Lett., 2011, 1, 1-12.
[14]
Jain, A.K.; Vaidya, A.; Ravichandran, V.; Kashaw, S.K.; Agrawal, R.K. Recent developments and biological activities of thiazolidinone derivatives: A review. Bioorg. Med. Chem., 2012, 20, 3378-3395.
[15]
Liu, L.; Siegmund, A.; Xi, N.; Lefko, P.K.; Rex, K.; Chen, A.; Lin, J.; Moriguchi, J.; Berry, L.; Huang, L.Y.; Teffera, Y.; Yang, Y.J.; Zhang, Y.H.; Bellon, S.F.; Lee, M.; Shimanovich, R.; Bak, A.; Dominguez, C.; Norman, M.H.; Harmange, J.C.; Dussault, I.; Kim, T.S. Discovery of a potent, selective, and orally bioavailable c-Met inhibitor: 1-(2-Hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy) pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458). J. Med. Chem., 2008, 51, 3688-3691.
[16]
Peach, M.L.; Tan, N.; Tan, N.; Choyke, S.J.; Giubellino, A.; Athauda, G.; Burke, T.R.; Nicklaus, M.C.; Bottaro, D.P. Directed discovery of agents targeting the met tyrosine kinase domain by virtual screening. J. Med. Chem., 2009, 52, 943-951.
[17]
Knudsen, B.S.; Gmyrek, G.A.; Inra, J.; Scherr, D.S.; Vaughan, E.D.; Nanus, D.M.; Kattan, M.W.; Gerald, W.L.; Woude, G.F. High expression of the Met receptor in prostate cancer metastasis to bone. Urology, 2002, 60, 1113-1117.
[18]
Humphrey, P.A.; Zhu, X.; Zarnegar, R.; Swanson, P.E.; Ratliff, T.L.; Vollmer, R.T.; Day, M.L. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am. J. Pathol., 1995, 147, 386-396.
[19]
Verras, M.; Lee, J.; Xue, H.; Li, T.H.; Wang, Y.; Sun, Z. The androgen receptor negatively regulates the expression of c-Met: Implications for a novel mechanism of prostate cancer progression. Cancer Res., 2007, 67, 967-975.
[20]
Bacco, F.D.; Luraghi, P.; Medico, E.; Reato, G.; Girolami, F.; Perera, T.; Gabriele, P.; Comoglio, P.M.; Boccaccio, C. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. J. Natl. Cancer Inst., 2011, 103, 645-661.
[21]
Zhu, W.; Wang, W.; Xu, S.; Wang, J.; Tang, Q.; Wu, C.; Zhao, Y.; Zheng, P. Synthesis, and docking studies of phenylpyrimidine-carboxamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety as c-Met inhibitors. Bioorg. Med. Chem., 2016, 24, 1749-1756.
[22]
Zhang, Z.; Lee, J.C.; Li, L.; Olivas, V.; Au, V.; LaFramboise, T.; Abdel-Rahman, M.; Wang, X.; Levine, A.D.; Rho, J.K.; Choi, Y.J.; Choi, C.M.; Kim, S.W.; Jang, S.J.; Park, Y.S.; Kim, W.S.; Lee, D.H.; Lee, J.S.; Miller, V.A.; Arcila, M.; Ladanyi, M.; Moonsamy, P.; Sawyers, C.; Boggon, T.J.; Ma, P.C.; Costa, C.; Taron, M.; Rosell, R.; Halmos, B.; Bivona, T.G. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat. Genet., 2012, 44, 852-860.
[23]
Li, S.; Huang, Q.; Liu, Y.; Zhang, X.; Liu, S.; He, C.; Gong, P. Design, synthesis and antitumour activity of bisquinoline derivatives connected by 4-oxy-3-fluoroaniline moiety. Eur. J. Med. Chem., 2013, 64, 62-73.
[24]
Dömling, A. Recent developments in isocyanide based multi-component reactions in applied chemistry. Chem. Rev., 2006, 106, 17-89.
[25]
Rivera, D.G.; León, F.; Concepción, O.; Morales, F.E.; Wessjohann, L.A. A multiple multi-component approach to chimeric peptide-peptoid podands. Chemistry Eur. J.,, 2013, 19, 6417-6428.
[26]
Ugi, I.; Werner, B.; Dömling, A. The chemistry of isocyanides, their multi-component reactions and their libraries. Molecules, 2003, 8, 53-66.
[27]
Van Berkel, S.S.; Bögels, B.G.; Wijdeven, M.A.; Westermann, B.; Rutjes, F.P. Recentadvances in asymmetric isocyanide-based multi-component reactions. Eur. J. Org. Chem., 2012, 2012, 3543-3559.
[28]
Rotstein, B.H.; Zaretsky, S.; Rai, V.; Yudin, A.K. Small heterocycles in multi-component reactions. Chem. Rev., 2014, 114, 8323-8359.
[29]
Lia, M.M.; Duana, C.S.; Yub, Y.Q.; Xua, D.Z. A general and efficient one-pot synthesis of spiro[2-amino-4H-pyrans] via tandem multi-component reactions catalyzed by Dabco-based ionic liquids. Dyes Pigments, 2018, 150, 202-206.
[30]
Keivanloo, A.; Kazemi, S.S.; Isfahani, H.N.; Bamoniri, A. Novel multi-component synthesis of 1,4-disubstituted pyrrolo[1,2-a]quinoxalines through palladium-catalyzed coupling reaction/hetero-annulation in water. Tetrahedron, 2016, 72, 6536-6542.
[31]
Bonsignore, L.; Loy, G.; Secci, D.; Calignano, A. Synthesis and pharmacological activity of 2-oxo-(2H) 1-benzopyran-3-carboxamide derivatives. Eur. J. Med. Chem., 1993, 28, 517-520.
[32]
Lu, Y.; Yan, Y.; Wang, L.; Wang, X.; Gao, J.; Xi, T.; Wang, Z.; Jiang, F. Design, facile synthesis and biological evaluations of novel pyrano[3,2-a]phenazine hybrid molecules as antitumor agents. Eur. J. Med. Chem., 2017, 127, 928-943.
[33]
Lu, Y.; Wang, L.; Wang, X.; Xi, T.; Liao, J.; Wang, Z.; Jiang, F. Design, combinatorial synthesis and biological evaluations of novel 3-amino-10-((1-aryl-1H-1,2,3-triazol-5-yl)methyl)-20-oxospiro [benzo[a] pyrano[2,3-c]phenazine-1,3′-indoline]-2-carbonitrile antitumorhybrid molecules. Eur. J. Med. Chem., 2017, 135, 125-141.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 19
ISSUE: 12
Year: 2019
Page: [1438 - 1453]
Pages: 16
DOI: 10.2174/1871520619666190416102144
Price: $65

Article Metrics

PDF: 32
HTML: 3